HSPB7

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, HSPB7 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HSPB7 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher HSPB7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSPB7 expression acts as an unfavorable survival marker.

SKCM and SARC are the cancer types where HSPB7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
SKCMDFSMedianIV0.0360.433<.0018view →
SARCDFSMedianAll0.1210.611.0416view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

HSPB7–SKCM (DFS)

Kaplan–Meier survival curve for HSPB7 mutant vs wild-type samples in SKCM.

Open the SKCM breakdown →

Exploration